WebJun 1, 2024 · BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) ... The present BYLieve study aims to assess the efficacy and safety of ALP + FUL/LET in … WebMay 6, 2024 · The combination of alpelisib (Piqray) plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer...
National Center for Biotechnology Information
WebFeb 15, 2024 · Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine … WebTo our knowledge, BYLieve is the first, prospective clinical study to examine the use of alpelisib plus fulvestrant for hormone receptor-positive, HER2-negative, PIK3CA … steps referral form east sussex
阿培利司/阿博利布(Alpelisib)联合氟维司群治疗晚期乳腺癌疗效如 …
WebOct 20, 2024 · Furthermore, we show a median PFS of 6.8 months, which is comparable to the 5.7 months reported by the BYLieve study (5, 6). Alpelisib is approved for treatment in the second-line metastatic setting. However, in our study, a large proportion of patients were heavily pretreated, likely due to an attempt to derive benefit from this medication ... WebFeb 15, 2024 · BYLieve (NCT03056755), an ongoing phase 2, multicenter, open-label, 3-cohort noncomparative study, is the first trial evaluating ALP + endocrine therapy (FUL or letrozole [LET]) in pts with PIK3CA -mutated, HR+, HER2- ABC who progressed on/after prior therapy, including CDK4/6i. WebSep 30, 2024 · alpelisib and fulvestrant; alpelisib and letrozole; Alpelisib is a tablet. You take the tablets once a day, every day. Letrozole is a tablet. You take the tablets once a day, every day. You have fulvestrant as 2 injections, one into each buttock. You have the injections: twice a month in the first month; then once a month steps redone